Cargando…

Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials

Detalles Bibliográficos
Autores principales:	Dummer, Reinhard, Schadendorf, Dirk, Ascierto, Paolo A, Larkin, James, Lebbé, Celeste, Hauschild, Axel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108862/ http://dx.doi.org/10.1186/1479-5876-12-S1-P8

Ejemplares similares

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
por: Ascierto, Paolo Antonio, et al.
Publicado: (2020)

Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg
por: Grimaldi, Antonio M, et al.
Publicado: (2014)

Correction: Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
Publicado: (2020)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
por: Dummer, Reinhard, et al.
Publicado: (2015)

The abscopal effect: efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg
por: Grimaldi, Antonio M, et al.
Publicado: (2013)

Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme
por: Altomonte, Maresa, et al.
Publicado: (2013)

Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma
por: Zimmer, Lisa, et al.
Publicado: (2015)

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma
por: Homicsko, Krisztian, et al.
Publicado: (2022)

Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire
por: Tarhini, Ahmad, et al.
Publicado: (2018)

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
por: Ascierto, Paolo A, et al.
Publicado: (2014)

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
por: Lebbé, Celeste, et al.
Publicado: (2019)

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial
por: Chesney, Jason A, et al.
Publicado: (2023)

Immunotherapy in non-melanoma skin cancer: updates and new perspectives
por: Ascierto, Paolo Antonio, et al.
Publicado: (2019)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports
por: Wilgenhof, Sofie, et al.
Publicado: (2012)

Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy‐naive advanced melanoma
por: Namikawa, Kenjiro, et al.
Publicado: (2020)

Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
por: Ascierto, Paolo A, et al.
Publicado: (2022)

Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
por: Piérard, Gérald E., et al.
Publicado: (2012)

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
por: Revicki, Dennis A, et al.
Publicado: (2012)

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
por: Pires da Silva, Ines, et al.
Publicado: (2022)

MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab
por: Bifulco, Carlo, et al.
Publicado: (2014)

Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients
por: Tallerico, Rossana, et al.
Publicado: (2015)

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
por: Queirolo, Paola, et al.
Publicado: (2014)

Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab
por: Koguchi, Yoshinobu, et al.
Publicado: (2015)

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
por: Ascierto, Paolo A, et al.
Publicado: (2012)

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
por: Voskens, Caroline J., et al.
Publicado: (2013)

Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
por: Zimmer, Lisa, et al.
Publicado: (2015)

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
por: Bhave, Prachi, et al.
Publicado: (2022)

Comparison of the anesthetic effects between 5 mg/kg of alfaxalone and 10 mg/kg of propofol administered intravenously in cats
por: TAMURA, Jun, et al.
Publicado: (2021)

Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma
por: Harder, Nathalie, et al.
Publicado: (2019)

Ipilimumab: Melanoma and beyond
por: Patel, Vishal, et al.
Publicado: (2011)

Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma
por: Stucci, Stefania, et al.
Publicado: (2015)

Ipilimumab in the treatment of metastatic melanoma: management of adverse events
por: Della Vittoria Scarpati, Giuseppina, et al.
Publicado: (2014)

Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders
por: Brown, Lauren J, et al.
Publicado: (2021)

Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy
por: Turiello, Roberta, et al.
Publicado: (2020)

Biomarkers in melanoma
por: Gogas, H., et al.
Publicado: (2009)

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma
por: van Herpen, Carla M.L., et al.
Publicado: (2019)

Comparison of the initial and residual speed of Ixodes scapularis kill on dogs treated with a single dose of Bravecto(®) Chew (25 mg/kg fluralaner) or Simparica TRIO(®) (1.2 mg/kg sarolaner, 24 µg/kg moxidectin, 5 mg/kg pyrantel)
por: Reif, Kathryn E., et al.
Publicado: (2023)

Evolving impact of long-term survival results on metastatic melanoma treatment
por: Michielin, Olivier, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p5flss7bieo9m6ddipv9q4e6gn